Giant Cell Arteritis Market Size (7MM) was ~USD 960 million in 2023 and it is expected to grow by 2034

The Giant Cell Arteritis Market in the 7MM was valued at ~USD 960 million in 2023, over the study period from 2020 to 2034. DelveInsight’s comprehensive market research provides critical insights into such market trends, enabling stakeholders to understand growth drivers, emerging opportunities, and potential challenges within the Giant Cell Arteritis Market Landscape. By analyzing historical data, current Giant Cell Arteritis Market Dynamics, and future projections, DelveInsight equips pharmaceutical companies, investors, and healthcare professionals with actionable intelligence to make informed strategic decisions, identify investment opportunities, optimize product positioning, and plan research and development initiatives effectively.

The Giant Cell Arteritis Market is increasingly guided by biomarker-driven strategies. Giant Cell Arteritis (GCA), also known as temporal arteritis, is a form of vasculitis—inflammation of the blood vessels—that primarily affects the large and medium-sized arteries, especially those in the head, temples, and scalp. It most commonly occurs in people over 50 years of age, with a higher prevalence in women.

DelveInsight’s report, “Giant Cell Arteritis Market Insights, Epidemiology, and Market Forecast-2034,” provides a comprehensive analysis of the Giant Cell Arteritis Market landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the prevalence, incidence, and patient demographics across key regions. Additionally, it examines Giant Cell Arteritis Market Dynamics, offering a thorough assessment of current and emerging market trends, treatment patterns, and therapeutic developments. The analysis spans major markets, including the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom), and Japan, equipping decision-makers with actionable intelligence for strategic planning, investment, and research initiatives.

To know in detail about the Giant Cell Arteritis Market Outlook, drug uptake, treatment scenario, and epidemiology trends, click here @ Giant Cell Arteritis Market Forecast

Key Takeaways from Giant Cell Arteritis Market Report

• The leading Giant Cell Arteritis Companies, such as AbbVie, CSL, Kiniksa Pharmaceuticals, Dr Reddys Laboratories, Eli Lilly and Company, Janssen Biotech, Johnson & Johnson, Kiniksa Pharmaceuticals, Ltd., MorphoSys AG, Novartis Pharmaceuticals, Roche Holding, XOMA, and others.

• Promising Giant Cell Arteritis Therapies such as Tocilizumab + Glucocorticoids (GCs), Baricitinib, Secukinumab 300 mg, s.c., Prednisolone, Adalimumab, Upadacitinib, Corticosteroid (CS), SPI-62 and others.

• The Giant Cell Arteritis Market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching multiple-stage Giant Cell Arteritis Pipeline products will significantly revolutionize the Giant Cell Arteritis Market Dynamics.

Giant Cell Arteritis Overview

Giant Cell Arteritis (GCA), also known as temporal arteritis, is an inflammatory disease of the blood vessels, primarily affecting the medium and large arteries, especially those in the head and neck, such as the temporal arteries. It is called “giant cell” because, under a microscope, the affected arteries often show multinucleated giant cells, which are a type of inflammatory immune cell.

Get a Free sample for the Giant Cell Arteritis Market Report @ https://www.delveinsight.com/report-store/giant-cell-arteritis-market 

Key Trends in the Giant Cell Arteritis Therapeutics Market

• Rising Geriatric Population

Giant Cell Arteritis primarily affects individuals above 50 years, with incidence increasing with age. The growing elderly population globally is significantly driving market demand for GCA diagnostics and therapeutics.

• Advancements in Diagnostic Techniques

The introduction of advanced imaging modalities like ultrasound, PET scans, and MRI for early and accurate detection of GCA is improving disease management and fueling market growth.

• Emergence of Biologic Therapies

Biologic agents, particularly IL-6 inhibitors, are revolutionizing GCA treatment. Drugs such as tocilizumab are gaining traction due to their efficacy in reducing steroid dependency and managing refractory cases.

• Shift Towards Steroid-Sparing Treatments

Chronic corticosteroid therapy, while effective, is associated with severe side effects. There is a growing trend toward adopting steroid-sparing agents and targeted therapies, enhancing patient safety and adherence.

• Focus on Personalized Medicine

Ongoing research is emphasizing patient-specific treatment strategies based on biomarkers and disease severity, paving the way for more precise and effective therapies in GCA.

• Expansion of Clinical Trials

Numerous global clinical trials are investigating novel therapeutics and combination regimens for GCA, highlighting increasing R&D investment and potential future market entrants.

• Increased Awareness and Early Detection

Awareness campaigns and physician education programs are improving early diagnosis and treatment initiation, which is critical for preventing severe complications like vision loss.

• Rising Healthcare Expenditure

Enhanced healthcare infrastructure and higher spending on autoimmune and inflammatory diseases are contributing to the growth of the GCA market worldwide.

Giant Cell Arteritis Epidemiology Segmentation in the 7MM

The Giant Cell Arteritis Market Report proffers epidemiological analysis for the study period 2020-2034 in the 7MM, segmented into-

• Giant Cell Arteritis Diagnosed prevalent cases
• Giant Cell Arteritis Region-specific cases
• Giant Cell Arteritis Subtype-specific cases
• Giant Cell Arteritis Gender-specific cases
• Giant Cell Arteritis Age-specific cases
• Giant Cell Arteritis Clinical manifestation-specific cases
• Total Giant Cell Arteritis Treated cases

Download the report to understand which factors are driving Giant Cell Arteritis Epidemiology trends @ Giant Cell Arteritis Epidemiology Forecast

Recent Development in the Giant Cell Arteritis Treatment Landscape

• In December 2025, Novartis Pharmaceuticals announced a study is to demonstrate the efficacy and safety of subcutaneously (s.c.) administered secukinumab 300 mg in combination with glucocorticoid taper regimen compared to placebo in combination with glucocorticoid taper regimen, in adult patients with new onset of giant cell arteritis (GCA) who are in clinical remission and who are eligible for treatment with glucocorticoid-monotherapy as per current clinical practice and treatment guidelines for the targeted participant population, thereby supporting health technology assessments (HTAs) of secukinumab in Germany.

Giant Cell Arteritis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential Giant Cell Arteritis drugs recently launched in the Giant Cell Arteritis market or expected to get launched during the study period. The analysis covers Giant Cell Arteritis Market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share. The report also covers the Giant Cell Arteritis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Giant Cell Arteritis Companies and Therapies

• Kiniksa Pharmaceuticals Ltd.: Prednisone
• Novartis Pharmaceuticals: Secukinumab
• Matthew J Koster: Baricitinib
• Hoffmann-La Roche: Tocilizumab
• AbbVie: Upadacitinib

To know more about Giant Cell Arteritis Companies working in the treatment market, visit @ Giant Cell Arteritis Clinical Trials and Therapeutic Assessment

Giant Cell Arteritis Market Drivers

• Rising Geriatric Population

The prevalence of GCA is higher among individuals aged 50 years and above. With the global aging population growing, the number of GCA cases is expected to increase, driving market demand for effective therapeutics.

• Increasing Disease Awareness

Enhanced awareness among healthcare professionals and patients about early diagnosis and management of GCA is contributing to improved detection rates, thereby boosting market growth.

• Advancements in Diagnostic Techniques

The adoption of advanced imaging modalities like ultrasound, PET scans, and MRI for early and accurate diagnosis of GCA is aiding timely treatment initiation, supporting market expansion.

• Approval of Novel Therapies

Introduction of targeted therapies such as biologics (e.g., IL-6 inhibitors) has revolutionized GCA management, offering alternatives to long-term corticosteroid use, and driving the market.

• Growing Preference for Biologic and Targeted Therapies

Patients and clinicians are increasingly opting for steroid-sparing treatments due to better efficacy and fewer side effects, supporting the adoption of novel GCA drugs.

• High Unmet Medical Need

Despite existing corticosteroid treatments, relapses and side effects are common, highlighting the need for safer and more effective therapies, thereby fueling research and market demand.

• Increased Clinical Trial Activity

Ongoing trials focused on novel agents for GCA are likely to result in new approvals and expanded treatment options, propelling market growth over the forecast period.

• Rising Healthcare Expenditure

Increased spending on healthcare and access to specialty care are facilitating early diagnosis and treatment, further driving market growth.

Giant Cell Arteritis Market Barriers

• Limited Awareness and Late Diagnosis

Many patients remain undiagnosed or are diagnosed late due to the non-specific early symptoms of GCA, which include headache, fatigue, and vision disturbances. This delays treatment initiation, limiting the eligible patient pool for therapies.

• Complexity of Disease Management

GCA often requires long-term corticosteroid therapy, which comes with significant side effects. The complexity of managing these side effects discourages some patients and clinicians from aggressive treatment approaches.

• High Cost of Emerging Therapies

Novel treatments, including biologics like IL-6 inhibitors, are expensive, limiting accessibility for patients, especially in regions with inadequate insurance coverage or healthcare infrastructure.

• Stringent Regulatory Requirements

The development of new GCA therapies faces strict regulatory scrutiny, including requirements for large-scale, long-duration clinical trials, making market entry challenging for new entrants.

• Limited Number of Clinical Trials

GCA is a rare disease, which constrains patient recruitment for clinical studies. Limited trial data slows the adoption of new therapies and affects confidence among physicians.

Scope of the Giant Cell Arteritis Market Report

• Coverage- 7MM
• Study Period- 2020-2034
• Giant Cell Arteritis Companies- AbbVie, CSL, Kiniksa Pharmaceuticals, Dr Reddys Laboratories, Eli Lilly and Company, Janssen Biotech, Johnson & Johnson, Kiniksa Pharmaceuticals, Ltd., MorphoSys AG, Novartis Pharmaceuticals, Roche Holding, XOMA, and others.
• Giant Cell Arteritis Therapies- Tocilizumab + Glucocorticoids (GCs), Baricitinib, Secukinumab 300 mg, s.c., Prednisolone, Adalimumab, Upadacitinib, Corticosteroid (CS), SPI-62 and others.
• Giant Cell Arteritis Therapeutic Assessment: Giant Cell Arteritis current marketed and Giant Cell Arteritis emerging therapies
• Giant Cell Arteritis Market Dynamics: Giant Cell Arteritis market drivers and Giant Cell Arteritis market barriers
• Giant Cell Arteritis Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Giant Cell Arteritis Unmet Needs, KOL’s views, Analyst’s views, Giant Cell Arteritis Market Access and Reimbursement

Discover more about therapies set to grab major Giant Cell Arteritis Market Share @ Giant Cell Arteritis Treatment Market

Table of Contents

1. Key Insights

2. Giant Cell Arteritis Market Report Introduction

3. Giant Cell Arteritis Market Overview at a Glance

4. Giant Cell Arteritis Executive Summary

5. Key Events

6. Giant Cell Arteritis Market Disease Background and Overview

7. Giant Cell Arteritis Methodology

8. Giant Cell Arteritis Population

9. Giant Cell Arteritis Patient Journey

10. Giant Cell Arteritis Marketed Drugs

11. Giant Cell Arteritis Emerging Drugs

12. Giant Cell Arteritis – 7MM Market Analysis

13. Giant Cell Arteritis KOL Views

14. Giant Cell Arteritis Unmet Needs

15. Giant Cell Arteritis SWOT Analysis

16. Giant Cell Arteritis Market Access and Reimbursement

17. Appendix

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.